At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 359 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
liraglutide 3.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
In Brief
A Phase 3 clinical trial evaluating liraglutide and placebo for Metabolism and Nutrition Disorder and 2 related conditions. Completed, enrolled 359 participants across 42 sites in 2 countries.
Detailed Summary
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartJun 2012
Primary CompletionJun 2013
Study CompletionJun 2013
TodayJul 2026
First PostedMar 19, 2012
Enrollment StartJun 7, 2012
Primary CompletionJun 1, 2013
Study CompletionJun 17, 2013
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 14.3 years ago
Interventions
liraglutidedrug
3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
placebodrug
Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise